Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine.
about
Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters.Regulation of ENT1 expression and ENT1-dependent nucleoside transport by c-Jun N-terminal kinase.Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors: IDENTIFICATION OF KEY hENT1 AMINO ACID RESIDUES FOR INTERACTION WITH BCR-ABL KINASE INHIBITORS.
P2860
Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Imatinib-resistant CML cells h ...... in sensitivity to gemcitabine.
@en
Imatinib-resistant CML cells h ...... in sensitivity to gemcitabine.
@nl
type
label
Imatinib-resistant CML cells h ...... in sensitivity to gemcitabine.
@en
Imatinib-resistant CML cells h ...... in sensitivity to gemcitabine.
@nl
prefLabel
Imatinib-resistant CML cells h ...... in sensitivity to gemcitabine.
@en
Imatinib-resistant CML cells h ...... in sensitivity to gemcitabine.
@nl
P2093
P2860
P1476
Imatinib-resistant CML cells h ...... in sensitivity to gemcitabine.
@en
P2093
Andrea V Leisewitz
Eric I Zimmerman
Lee M Graves
Shannon Z Jones
P2860
P304
P356
10.1080/15257770802145892
P577
2008-06-01T00:00:00Z